✦ LIBER ✦

Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results

✍ Scribed by Chiesa, F.; Tradati, N.; Marazza, M.; Rossi, N.; Boracchi, P.; Mariani, L.; Clerici, M.; Formelli, F.; Barzan, L.; Carrassi, A.; Pastorini, A.; Camerini, T.; Giardini, R.; Zurrida, S.; Minn, F.L.; Costa, A.; De Palo, G.; Veronesi, U.

Book ID: 121969924
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 709 KB
Volume: 28
Category: Article
ISSN: 0964-1955
DOI: 10.1016/0964-1955(92)90035-Y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial of fenretinide (4-HPR)

Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long-term results

✍ Fausto Chiesa; Nicoletta Tradati; Roberto Grigolato; Patrizia Boracchi; Elia Big 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 84 KB

## Abstract We assessed the efficacy of fenretinide at preventing relapses, new lesions and carcinomas after surgical excision of oral leukoplakia. In a controlled multicenter study, 170 patients operated on for oral leukoplakias with benign postoperative histology were randomized to 200 mg fenreti